Purpose: Three founder mutations in BRCA1 or BRCA2 genes increase breast cancer risk among Ashkenazi Jewish women. Reported estimates of the magnitude of this risk vary widely. We describe an integrated approach for assessing the plausibility of these estimates. Methods: Our approach integrates four epidemiologic parameters:
Three specific mutations account for approximately 85% of the mutations found in the BRCA1 (185delAG and 5382insC) and BRCA2 (6174delT) genes among the Ashkenazi Jewish population. 1 The prevalence of these three mutations is approximately 10 times that of all BRCA1 and BRCA2 mutations among the general U.S. population. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] The risk of developing breast and ovarian cancer is significantly increased in women who carry one (or more) of these three founder mutations, although the magnitude of risk is less certain.
Four epidemiologic parameters must be known to accurately determine the burden of these three mutations in breast cancer cases among Ashkenazi Jewish women: (1) the proportion of all breast cancer cases associated with one of the three mutations (clinical sensitivity), (2) the proportion of women with one of the three mutations that will develop breast cancer (penetrance), (3) the prevalence of these three mutations among all women (carrier rate), and (4) the number of women that will develop breast cancer by a given age, regardless of mutation status (cumulative incidence).
To date, individual studies have derived estimates for between one and three of these epidemiologic parameters. 2-7,14 -17 Their estimates have not always been consistent, either with each other or internally. In order to be internally consistent, any given parameter estimate reported by a study needs to fall within a range of values that is determined by the remaining three epidemiologic parameter values. The present analysis is based on recognition that estimates for these four epidemiologic parameters are interdependent and can be evaluated and refined by entering them into a mathematical equation. To our knowledge, this is the first attempt to reconcile estimates of these parameters using such an integrated approach.
MATERIALS AND METHODS
The four interdependent epidemiologic parameters used in our approach are described here and in Table 1 .
(1) Proportion of Ashkenazi Jewish women with breast cancer that has one of the three BRCA1 or BRCA2 founder mutations (clinical sensitivity) Direct estimates have been made for the proportion of population-based breast cancer cases at various ages associated with these mutations. 2,14 -16 The range of these estimates is reported in Table 1 . The estimates of clinical sensitivity are heterogeneous. Therefore, rather than providing a summary estimate in our integrated approach, we provide a sensitivity analysis over the range of estimates. The sensitivity analysis is appropriate when there is not consensus about what value should be assigned to a given parameter.
(2) Proportion of women with one of the three BRCA1 or BRCA2 founder mutations that develops breast cancer (penetrance)
Penetrance estimates for founder mutations have been reported for the Ashkenazi Jewish population. 2,7,14 -17 These estimates were derived indirectly, using a variety of methodologies. Table 1 shows that these point estimates cover a broad range. Some of the corresponding confidence intervals are also wide, indicating that the estimates are not precise. For these reasons, we include a sensitivity analysis for this variable in our integrated approach. The risk of breast cancer for BRCA1 founder mutation carriers is likely to be different than that for BRCA2 founder mutation carriers. The 6174delT mutation in BRCA2 falls within the ovarian cancer cluster region. There is evidence to suggest that carriers of mutations in this region have a decreased risk of breast cancer compared with other mutation carriers. 18, 19 Three studies that provide mutation status for all three founder mutations in women with breast cancer report that the two BRCA1 founder mutations (185delAG, 5382insC) represent between 64% and 72% of the three founder mutations. 14 -16 A weighted, combined penetrance estimate for all three founder mutations up to ages 40, 50, and 70 is used in our approach. Ages 40 and 50 were selected to show the contribution of founder mutations to early onset breast cancer. Age 70 was selected because all studies give a penetrance estimate to at least this age. This proportion has been directly estimated by several studies 2-7 and can be expressed as a carrier rate (e.g., 2.0% ϭ 1 in 50). Table 1 shows the range of these estimates for each mutation, along with a consensus estimate range for all three. There are no published population-based estimates available that report the cumulative incidence of breast cancer specifically for U.S. Ashkenazi Jewish women. An estimate of breast cancer incidence among Israeli Jews born in Europe or North America (8.17%, 1988 -1992 20 ) is lower than that in U.S. Caucasian women (8.96%, 1993-1995 21 ). There is evidence to suggest that there is little or no difference in breast cancer risk between Ashkenazi Jewish women and the overall general population of Caucasian women in the U.S. [22] [23] [24] [25] We used the Dev- Founder mutation penetrance estimates
Can software, 21 which uses the age-conditional probabilities by 5-year intervals, 26 to estimate the proportions of a theoretical cohort of one million 20-year-old Caucasian women in the U. S. general population who will develop breast cancer by ages 40, 50, and 70. These proportions are used as surrogate estimates for Ashkenazi Jewish women. Twenty years of age is selected as the starting reference point because BRCA1 and BRCA2 mutation testing is recommended almost exclusively for adults, and because the incidence of breast cancer before age 20 is nearly zero. Ages 40 and 50 were selected to show the contribution of founder mutations to early onset breast cancer. We selected 70 years of age because all of the studies report the proportion of women with a mutation that develops breast cancer at least up to this age. Our integrated approach defines the relationship among the four epidemiologic parameters in a hypothetical cohort of one million 20-year-old Ashkenazi Jewish women followed to ages 40, 50, and 70 and is derived from Bayes theorem. This integrated approach is represented by the following equation:
Cumulative incidence (%) ϭ ͑͑p ϫ 1,000,000͒/cs͒ ϫ cf where p ϭ combined penetrance of three founder mutations (%), cs ϭ clinical sensitivity of founder mutations (%), and cf ϭ carrier frequency (carrier rate expressed as a percentage, %). Any three of these epidemiologic parameter estimates can be used to compute the fourth. This integrated approach is then applied to data from four studies that report estimates for the proportion of women with breast cancer and a founder mutation (clinical sensitivity), along with penetrance. 2,14 -16 Table 2 shows a two-way sensitivity analysis for penetrance of the three BRCA1 and BRCA2 founder mutations and the proportion of breast cancer cases associated with one of these mutations in a theoretical cohort of one million 20-year-old Ashkenazi Jewish women, assuming a mutation carrier rate of 1 in 40. The upper and lower limits for proportions of breast cancer cases with a mutation (columns) and penetrance (rows) are taken from Table 1 . The associated cumulative incidences (table entries) are then computed for each combination, according to our equation. For example, by age 70 years, with mutations present in 10% of cancer cases and a mutation penetrance of 40%, the cumulative incidence of breast cancer is computed to be 100,000 out of 1,000,000 women (boxed entry in Table 1 ). Figure 1 shows how this calculation is made.
RESULTS
In order to focus on plausible combinations of the four epidemiologic parameters, we have bolded selected entries in Table 2 , when all parameters are internally consistent (e.g., the computed cumulative incidence based on the other parameters is within 10% of the cumulative incidence in U.S. Caucasian women). In the top section of Table 2 , the data show that when between 30% and 40% of breast cancer cases by age 40 is associated with a founder mutation, the mutation carrier rate is 1 in 40, and the cumulative incidence of breast cancer cases is 0.5% (Ϯ 10%), the penetrance of founder mutations must be approximately 6% to 8%. Similarly, the bottom section of Table 2 shows that penetrance to age 70 must be between 30% and 50%. Collectively, the three sections of Table 2 show that the Table 2 Cumulative incidence of breast cancer among one million Ashkenazi Jewish women derived using the interrelationships among the proportion of women with breast cancer that has a BRCA1 or BRCA2 founder mutation, the penetrance of founder mutations, and the founder mutation carrier rate of 1 in 40 Bolded items represent plausible combinations of the four epidemiologic parameter estimates and the boxed item represents the combination used in Fig. 1 (see text) .
proportion of breast cancer cases associated with a founder mutation decreases with age and the penetrance increases with age.
Although the mutation carrier rate of 1 in 40 among Ashkenazi Jewish women is commonly reported, the published estimates range from 1 in 33 to 1 in 56. If the higher carrier rate of 1 in 33 is entered into the analysis described above, the proportion of breast cancer cases by age 70 associated with a BRCA1 or BRCA2 founder mutation will lie between 9 and 12%, and the mutation penetrance to age 70 will be between 30% and 40% (data not shown). If the lower carrier rate of 1 in 56 is used and between 7% and 12% of breast cancer cases are associated with a BRCA1 or BRCA2 founder mutation, then penetrance will lie between 40% and 70% (data not shown). Similar effects in clinical sensitivity and penetrance are found in breast cancer cases by ages 40 and 50 (data not shown).
Four studies report estimates for the proportion of Ashkenazi Jewish women with breast cancer and a founder mutation, along with penetrance of these mutations. 2,14 -16 The four epidemiologic parameters that are reported by and derived from these studies are summarized in Table 3 . In two of these studies, the estimates reported are internally consistent. 14, 15 The calculated cumulative incidence estimates of 107,800 and 99,000 using data from the studies by Warner et al. 14 and Satagopan et al. 15 , respectively, are within 7% of the SEER estimate (101,200). The population investigated by Fodor et al. 2 was also included in study by Satagopan et al. 14 ; a low penetrance estimate was reported for 185delAG and 6174delT mutations (36% to age 85), relative to other published penetrance estimates. The penetrance of 5382insC is not estimated, due to the low number of carriers. The proportion of women with breast cancer and a BRCA1 or BRCA2 founder mutation is also lower, at approximately 7%. This study estimates the founder mutation carrier rate to be 1 in 45. When these estimates are used in our integrated approach, a cumulative incidence of 114,300 breast cancer cases is expected. Surveillance, Epidemiology and End Results (SEER) estimates a cumulative incidence of 157,400 to age 85. Thus, with a difference of over 40%, these data are not likely to be internally consistent. Conversely, King et al. 16 report a high penetrance estimate for BRCA1 and BRCA2 founder mutations (71%) and a clinical sensitivity of 10%. When these estimates are used in our integrated approach, along with a generally agreed upon founder mutation carrier rate of 1 in 40, the cumulative incidence is 177,500 by Fig. 1. Flowchart showing an example of how the four epidemiologic parameters are related. In this example, a hypothetical cohort of one million Ashkenazi Jewish women is followed from age 20 to age 70. If the BRCA1 and BRCA2 mutation carrier rate is 1 in 40, then 25,000 mutation carriers are expected. Among these 25,000 mutation carriers, 10,000 (40% penetrance, Table 2 ) will develop breast cancer. When the clinical sensitivity estimate of 10% is applied (from Table 2 ), 90,000 women among nonmutation carriers are expected to develop breast cancer (10,000 / 0.1). The cumulative incidence is, therefore, 100,000 or 10%. Numbers in the remaining boxes in Fig. 1 are computed by subtraction. age 70. This is nearly 80% greater than the SEER estimate of about 100,000. These data are clearly not internally consistent.
DISCUSSION
We developed the methodology described in this study to reconcile individual estimates of four epidemiologic parameters that have varying degrees of reliability, by integrating them into a single mathematical equation. Our study utilizes the inherent relationship among the four epidemiologic parameters. The estimate for any one parameter within the equation is constrained by the estimate (or range of estimates) for the other three. Based on published data, our integrated approach shows that, for Ashkenazi Jewish women, a combined BRCA1 and BRCA2 founder mutation penetrance estimate for breast cancer by ages 40, 50, and 70 is most likely to lie between 6% and 8%, 15% and 22%, and 30% and 50%, respectively. These penetrance estimates may not be generalizable to all Jewish women with a BRCA1 or BRCA2 mutation that is not one of the three founder mutations. However, in a similar analysis conducted using epidemiologic parameter estimates for the general U. S. population, the penetrance to age 70 for all BRCA1 and BRCA2 mutations was between 35% and 65%. 31 In our integrated approach, the penetrance estimates for BRCA1 and BRCA2 founder mutations are combined. Differences in breast cancer risk have been reported for these three mutations. In addition, the 6174delT mutation in BRCA2 falls within the ovarian cancer cluster region. There is evidence to suggest that carriers of mutations in this region have a decreased risk of breast cancer compared with other mutation carriers. 18, 19 We have addressed these differences in risk by utilizing a weighted average. Alternatively, our integrated approach could also be used for each mutation or mutations in each gene. The clinical sensitivity and penetrance estimates used in this approach were derived from population-based cohorts. Estimates for these parameters obtained from families with multiple and/or early onset breast cancer cases are higher. Furthermore, there may be variations in penetrance due to environmental or gene modifiers. Although these penetrance variations cannot currently be measured, they are likely to be over-represented in the high-risk-based estimates.
There are two potential reasons why these penetrance and cumulative incidence estimates may be slightly underestimated. First, women carrying a BRCA1/2 mutation are at increased risk of dying at a younger age due to ovarian cancer and would therefore not develop breast cancer later in life (assuming they had not developed breast cancer before ovarian cancer). This is not likely to impact the estimates because the cumulative incidence of ovarian cancer is between five and nine times less than that of breast cancer, 21 depending on the age cutoff selected. Second, mutation carriers are more likely to undergo risk reducing surgeries (mastectomy and/or oophorectomy). The impact of the surgeries depends on the proportion of mutation carriers that selects these preventive strategies, which is currently relatively low among mutation carriers in the United States. [27] [28] [29] [30] A limitation of this study is that there is no reliable estimate for the cumulative incidence of breast cancer among Ashkenazi Jewish women in the United States. There is no substantial evidence that this cumulative incidence is significantly different from that in the U.S. Caucasian population, which we have used as a surrogate estimate in our integrated approach. In fact, our analysis suggests that the cumulative incidence of breast cancer among Ashkenazi Jewish women is likely to be within 10% of that in the U.S. Caucasian population.
Our study finds that BRCA1 and BRCA2 founder mutation penetrance is not likely to be as high at any age as those recently reported by King et al. 16 The penetrance estimates generated from our integrated approach are consistent with earlier published reports in this population. 2, 14, 15 Our finding has implications for Ashkenazi Jewish women considering BRCA1 and BRCA2 mutation testing and/or breast and ovarian cancer prevention strategies. These results also have a broader impact for public health genetics by better understanding the burden of these founder mutations on breast cancer in the U.S.
